•  Supplied as a lyophilized powder vial, manufactured to the highest chemical standards. Every batch is strictly synthesized as a reference standard for laboratory   evaluation, in-vitro testing, and scientific development purposes. 
•  Each size variation is accompanied by an independent third-party Certificate of Analysis (COA) verifying a purity level of 99% or higher, ID, net vial content, endotoxins, and vial conformity.
•  Laboratory Research Notice: This product is intended strictly for laboratory research and development use only.

Retatrutide

Clinical data
Other names	LY-3437943
Identifiers
IUPAC name
CAS Number	2381089-83-2
UNII	NOP2Y096GV
ChEMBL	ChEMBL5095485
Chemical and physical data
SMILES

• A¹ – 2-aminoisobutyric acid (Aib).
• L² – leucine modified with an α-methyl substituent (MeL, 2-methylleucine).
• S³ – L-serinamide (L–serine with the carboxylic acid group replaced with a carboxamide).
• K⁴ – L–lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ-Glu)-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides).

GLP3/Reta is synthetically engineered and produced using solid-phase peptide synthesis (SPPS). This is when amino acids are added to a peptide chain and attached to solid resin forming a backbone. After the backbone is synthesized, the molecule is cleaved chemically, then purified. Lipidation modifications also occur, meaning a fatty-acid side chain is added to promote reversible binding to albumin. This modification allows for a longer drug half-life..